Moderna MRNA Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Contract with Customer, Liability by Product | |||||
| Net product sales | $626M-67.9% | $1.95B-65.3% | $5.63B-66.8% | $16.95B-42.9% | |
| Other revenue | $412M— | —— | —— | —— | |
| Total Revenue by Geography | |||||
| Europe | $53M-91.1% | $598M-55.9% | $1.36B-80.1% | $6.82B-0.5% | |
| Rest of world | $692M-18.9% | $853M-76.3% | $3.6B-50.7% | $7.3B+34.0% | |
| United States | $1.2B-32.8% | $1.79B-5.8% | $1.9B-63.2% | $5.15B-16.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Moderna break its business down?
- Moderna (MRNA) reports contract with customer, liability by product across 2 parts — Net product sales and Other revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Moderna's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Moderna's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
